Clinical trials: Stage I Prostate Adenocarcinoma
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients with hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01848067
- Testing
- Alisertib, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
This phase I trial studies the side effects and best dose of niclosamide when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread from the primary site to other places…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT02532114
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Niclosamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Breast Cancer, Colorectal Cancer
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00667641
- Testing
- bortezomib, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Conditions
- Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01434290
- Testing
- 36.25 Gy IMRT, 51.6 Gy IMRT
- Where
- 37 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma, PSA Failure
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not…
- Conditions
- Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT04519879
- Testing
- Clinical Observation, Patient Observation, Questionnaire Administration
- Where
- 7 sites in United States
- Volunteers
- 133 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to determine the effectiveness of genistein in treating patients who have…
- Trial name
- NCT00005827
- Testing
- genistein
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04037254
- Testing
- Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
- Where
- 95 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- NRG Oncology
Prostate Cancer
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of androgens made by the body.
- Trial name
- DART (NCT00651326)
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 13 sites in Canada
- Volunteers
- 48 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer, Prostate Adenocarcinoma
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate…
- Trial name
- NCT04486755
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01787331
- Testing
- Itraconazole, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00526591
- Testing
- Everolimus, conventional surgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Jorge A. Garcia, MD
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and…
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04501913
- Testing
- Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
This randomized phase II trial will evaluate if a low omega-6, high omega-3 fat diet combined with fish oil has the potential to delay disease progression in patients with prostate cancer undergoing active surveillance.
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02176902
- Testing
- behavioral dietary intervention, omega-3 fatty acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer
RATIONALE: Studying changes in thymus function in patients who have been undergoing androgen blockade therapy for prostate cancer may help doctors learn more about how well patients will respond to treatment, may help in planning…
- Trial name
- NCT00379119
- Testing
- diagnostic laboratory biomarker analysis, flow cytometry, physiologic testing
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer
RATIONALE: A low-fat, high-fiber diet may slow the growth of prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of a low-fat, high-fiber diet with that of a standard diet in treating patients who…
- Trial name
- NCT00020995
- Testing
- therapeutic dietary intervention
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Radiation Toxicity
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00003307
- Testing
- amifostine trihydrate, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Arizona
Prostate Adenocarcinoma, Stage I Prostate Cancer
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01325311
- Testing
- Cholecalciferol, Genistein, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)